Switch theme
Sign up to access all valuation multiples
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
2014
477
LTM Revenue $217M
LTM EBITDA -$6.2M
$354M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Treace Medical Concepts has a last 12-month revenue (LTM) of $217M and a last 12-month EBITDA of -$6.2M.
In the most recent fiscal year, Treace Medical Concepts achieved revenue of $209M and an EBITDA of -$42.1M.
Treace Medical Concepts expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Treace Medical Concepts valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $217M | XXX | $209M | XXX | XXX | XXX |
| Gross Profit | $174M | XXX | $168M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | -$6.2M | XXX | -$42.1M | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -20% | XXX | XXX | XXX |
| EBIT | -$52.2M | XXX | -$55.7M | XXX | XXX | XXX |
| EBIT Margin | -24% | XXX | -27% | XXX | XXX | XXX |
| Net Profit | -$53.2M | XXX | -$55.7M | XXX | XXX | XXX |
| Net Margin | -25% | XXX | -27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $42.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Treace Medical Concepts's stock price is $6.
Treace Medical Concepts has current market cap of $361M, and EV of $354M.
See Treace Medical Concepts trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $354M | $361M | XXX | XXX | XXX | XXX | $-0.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Treace Medical Concepts has market cap of $361M and EV of $354M.
Treace Medical Concepts's trades at 1.7x EV/Revenue multiple, and -8.4x EV/EBITDA.
Equity research analysts estimate Treace Medical Concepts's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Treace Medical Concepts has a P/E ratio of -6.8x.
See valuation multiples for Treace Medical Concepts and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $361M | XXX | $361M | XXX | XXX | XXX |
| EV (current) | $354M | XXX | $354M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | -57.2x | XXX | -8.4x | XXX | XXX | XXX |
| EV/EBIT | -6.8x | XXX | -6.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.8x | XXX | -6.5x | XXX | XXX | XXX |
| EV/FCF | -9.6x | XXX | -7.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTreace Medical Concepts's last 12 month revenue growth is 9%
Treace Medical Concepts's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Treace Medical Concepts's rule of 40 is -12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Treace Medical Concepts's rule of X is 20% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Treace Medical Concepts and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -20% | XXX | XXX | XXX |
| EBITDA Growth | -162% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -12% | XXX | -11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 20% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 107% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Treace Medical Concepts acquired XXX companies to date.
Last acquisition by Treace Medical Concepts was XXXXXXXX, XXXXX XXXXX XXXXXX . Treace Medical Concepts acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Treace Medical Concepts founded? | Treace Medical Concepts was founded in 2014. |
| Where is Treace Medical Concepts headquartered? | Treace Medical Concepts is headquartered in United States of America. |
| How many employees does Treace Medical Concepts have? | As of today, Treace Medical Concepts has 477 employees. |
| Who is the CEO of Treace Medical Concepts? | Treace Medical Concepts's CEO is Mr. John T. Treace. |
| Is Treace Medical Concepts publicy listed? | Yes, Treace Medical Concepts is a public company listed on NAS. |
| What is the stock symbol of Treace Medical Concepts? | Treace Medical Concepts trades under TMCI ticker. |
| When did Treace Medical Concepts go public? | Treace Medical Concepts went public in 2021. |
| Who are competitors of Treace Medical Concepts? | Similar companies to Treace Medical Concepts include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Treace Medical Concepts? | Treace Medical Concepts's current market cap is $361M |
| What is the current revenue of Treace Medical Concepts? | Treace Medical Concepts's last 12 months revenue is $217M. |
| What is the current revenue growth of Treace Medical Concepts? | Treace Medical Concepts revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Treace Medical Concepts? | Current revenue multiple of Treace Medical Concepts is 1.6x. |
| Is Treace Medical Concepts profitable? | Yes, Treace Medical Concepts is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Treace Medical Concepts? | Treace Medical Concepts's last 12 months EBITDA is -$6.2M. |
| What is Treace Medical Concepts's EBITDA margin? | Treace Medical Concepts's last 12 months EBITDA margin is -3%. |
| What is the current EV/EBITDA multiple of Treace Medical Concepts? | Current EBITDA multiple of Treace Medical Concepts is -57.2x. |
| What is the current FCF of Treace Medical Concepts? | Treace Medical Concepts's last 12 months FCF is -$37.0M. |
| What is Treace Medical Concepts's FCF margin? | Treace Medical Concepts's last 12 months FCF margin is -17%. |
| What is the current EV/FCF multiple of Treace Medical Concepts? | Current FCF multiple of Treace Medical Concepts is -9.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
